Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04699461
Title Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ADC Therapeutics S.A.
Indications

follicular lymphoma

Therapies

Idelalisib

Loncastuximab tesirine-lpyl

Age Groups: senior | adult
Covered Countries USA | ITA | FRA | ESP | BEL


No variant requirements are available.